<code id='236DF789F4'></code><style id='236DF789F4'></style>
    • <acronym id='236DF789F4'></acronym>
      <center id='236DF789F4'><center id='236DF789F4'><tfoot id='236DF789F4'></tfoot></center><abbr id='236DF789F4'><dir id='236DF789F4'><tfoot id='236DF789F4'></tfoot><noframes id='236DF789F4'>

    • <optgroup id='236DF789F4'><strike id='236DF789F4'><sup id='236DF789F4'></sup></strike><code id='236DF789F4'></code></optgroup>
        1. <b id='236DF789F4'><label id='236DF789F4'><select id='236DF789F4'><dt id='236DF789F4'><span id='236DF789F4'></span></dt></select></label></b><u id='236DF789F4'></u>
          <i id='236DF789F4'><strike id='236DF789F4'><tt id='236DF789F4'><pre id='236DF789F4'></pre></tt></strike></i>

          Home / hotspot / focus

          focus


          focus

          author:knowledge    Page View:5
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In